Viridian Therapeutics, Inc.\DE— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$899M
↑+21.1% +$157Mvs FY2024
Total Liabilities
$177M
↑+150.5% +$106Mvs FY2024
Equity
$722M
↑+7.5% +$51Mvs FY2024
Cash
$875M
↑+21.9% +$157Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $899M | $742M |
| Current Assets | $894M | $738M |
| Cash | $875M | $718M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $20M | $21M |
| Non-Current Assets | $5M | $4M |
| PPE | $1M | $1M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $4M | $3M |
| Total Liab+Eq | $899M | $742M |
| Current Liab. | $71M | $48M |
| Accounts Payable | $9M | $2M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $367K | $288K |
| Other CL | $62M | $45M |
| Non-Current Liab. | $107M | $23M |
| Long-Term Debt | $0 | $21M |
| Other LT Liab. | $107M | $2M |
| Equity | $722M | $672M |
| Retained Earnings | $1.34B | $996M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · VRDN · Comparing FY2025 vs FY2024